Zone IVb stability requirements for Kenya PPB registrations: what your dossier must demonstrate

ICH Q1A(R2) defines four climatic zones for stability testing. Kenya sits firmly within Zone IVb, defined as hot and very humid, with reference conditions of 30°C and 75% relative humidity. This is the most demanding standard globally and applies to long-term, intermediate, and accelerated studies submitted to the Pharmacy and Poisons Board.

For finished product manufacturers registering in Kenya, this means that stability data generated under Zone IVa (30°C/65% RH) conditions, which is acceptable in some markets, is not automatically transferable. The PPB expects dossiers to include data specifically generated or scientifically justified for Zone IVb conditions across the proposed shelf life. Teams that assume Zone IVa data will be accepted without a formal bridging justification frequently face queries at the evaluation stage.

The zone requirement also applies to the proposed storage condition statement on the product label and in Module 2.3.P.8 of the dossier. Inconsistency between the storage conditions stated in the stability protocol, the finished product specification, and the product information leaflet is one of the most common consistency failures the PPB raises at screening.

A compliant stability package for a Kenya PPB new registration should include real-time data for the proposed shelf life or, where data is not yet complete, a statistical analysis justifying the proposed expiry period. For oral solid dosage forms, a minimum of 12 months of real-time Zone IVb data is expected at the time of submission for most new registrations, with a commitment to continue studies through the full shelf life.

Accelerated studies at 40°C/75% RH must cover at least six months. Where accelerated results show significant change, intermediate studies at 30°C/65% RH should also be included. Photostability testing under ICH Q1B is expected for products where light exposure is a risk factor, particularly for topical and ophthalmic products. The stability study design, including sampling timepoints, test parameters, acceptance criteria, and statistical model, should be fully described in Module 3.2.P.8.1 and cross-referenced consistently with the finished product specification in 3.2.P.5.

One area that creates repeated queries is the container closure system. The PPB requires that stability studies be conducted in the final proposed commercial packaging. Where a product is submitted in different pack sizes or configurations, bracketing and matrixing designs are permitted but must be scientifically justified with reference to ICH Q1D. Using studies from a different container closure system without documented equivalence is a common gap in dossiers compiled for other markets and repurposed for Kenya.

Stability data is not static. Studies continue through post-registration, and data generated after the initial submission may be required to support renewals or variations. Maintaining a clear record of which stability batches are on study, which timepoints have been tested, and how results compare to the registered specification limits is an ongoing operational requirement, not just a submission exercise.

For RA teams managing multiple products, the challenge is tracking which stability commitments were made at registration, what data has since accumulated, and whether any out-of-trend or out-of-specification results need to be escalated or reported to the PPB. Where these records exist in disconnected spreadsheets and email threads, gaps emerge precisely when you need the data: at renewal, in response to a query, or when a batch failure triggers an investigation.

Dossierly supports this by linking stability documentation to the specific project requirements and CTD sections they satisfy, so that when a follow-on study is completed, the dossier record can be updated and the evidence trail remains intact. The cross-document review feature flags specification limit discrepancies between the stability protocol and the current finished product specification, reducing the risk of dossier inconsistencies surviving into the next variation cycle.